SBIR/STTR Research Award

Mimic Peptides of HIV1 Epitopes as Vaccines

Award identifier 4b93ad340773a9604129467a2bd3e1d592c8a338bc60d737bc051d66dadb77afAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,994

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Mixture Sciences, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by Applicant): Despite current aggressive treatment protocols based on powerful drug combinations, the incidence of HIV-1 infection is increasing, from already very large numbers, mainly in developing countries that can least afford these newer drug regimens. The objective of this proposal combines the technologies of T cell immunobiology and synthetic peptide chemistry in a strategy of antigen discovery and optimization to identify individual candidate peptide sequence mimics for HIV-1 gag protein fragments as starting points in the design of preventive and therapeutic vaccines. Individual lines and clones of human cytotoxic T lymphocytes (CTL) having relevant lytic specificity for HIV peptide pulsed target cells will be used to screen very large combinatorial peptide libraries for peptide sequences that best stimulate proliferative, cytokine release, or lytic responses by these CTL clones. Candidate sequences deduced from each clonal scan will be synthesized and each individually assessed for activity on the selecting clone. The most effective peptide sequences will then be made available for ex vivo immunogenicity assessments and for phase I/II toxicity/efficacy clinical trials. Preliminary studies indicate that these library scans identify peptides several orders of magnitude more effective than native peptide ligands used to generate a particular T cell clone, and that these optimized superagonist peptides are effective as vaccines, provoking strong T cell mediated immune responses against native peptide ligands. PROPOSED COMMERCIAL APPLICATION: Not Available

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.